Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes

被引：0
|
作者：
Boris Kovatchev
Zhaoling Meng
Anna M. G. Cali
Riccardo Perfetti
Marc D. Breton
机构：
[1] University of Virginia,Center for Diabetes Technology
[2] Sanofi,undefined
[3] Sanofi,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Basal insulin; Glycaemic variability; Hypoglycaemia; Insulin glargine; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1293 / 1302
页数：9
相关论文
共 50 条
  • [31] EVALUATION OF PATIENT REPORTED SATISFACTION AND CLINICAL EFFICACY OF INSULIN GLARGINE 300 U/ML VERSUS 100 U/ML IN PATIENTS WITH TYPE 1 DIABETES
    Al Hayek, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A104 - A105
  • [32] Similar glycaemic control and less or comparable hypoglycaemia with insulin glargine 300 U/ml vs degludec 100 U/ml in insulin naive type 2 diabetes: the BRIGHT randomised study
    Cheng, A.
    Rosenstock, J.
    Ritzel, R.
    Bosnyak, Z.
    Devisme, C.
    Stella, P.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Bolli, G. B.
    DIABETOLOGIA, 2018, 61 : S42 - S42
  • [33] Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus
    Linari, Guido
    Fleeman, Linda
    Gilor, Chen
    Giacomelli, Lucia
    Fracassi, Federico
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2022, 24 (02) : 168 - 176
  • [34] Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
    Lau, Ip Tim
    Lee, Ka Fai
    So, Wing Yee
    Tan, Kathryn
    Yeung, Vincent Tok Fai
    DIABETES METABOLIC SYNDROME AND OBESITY, 2017, 10 : 273 - 284
  • [35] Glycaemic control and hypoglycaemia during 12months of randomized treatment with insulin glargine 300U/mL versus glargine 100U/mL in people with type 1 diabetes (EDITION 4)
    Home, Philip D.
    Bergenstal, Richard M.
    Bolli, Geremia B.
    Ziemen, Monika
    Rojeski, Maria
    Espinasse, Melanie
    Riddle, Matthew C.
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 121 - 128
  • [36] Comparative effectiveness of insulin glargine 300 U/mL and insulin degludec 100 U/mL in insulin naive type 2 diabetes adults: the Restore-2 naive cohort
    Fadini, G. P.
    Buzzetti, R.
    Larosa, M.
    Rossi, M. C.
    Nicolucci, A.
    Cucinotta, D.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 74 - 74
  • [37] New insulin glargine 300U/ml in people with Type 2 diabetes using basal insulin plus oral glucose lowering drugs compared with glargine 100U/ml (EDITION 2): less nocturnal hypoglycaemia and weight gain
    Home, P. D.
    Riddle, M. C.
    Bergenstal, R. M.
    Bolli, G. B.
    Wardecki, M.
    Maroccia, M.
    Yki-Jarvinen, H.
    DIABETIC MEDICINE, 2015, 32 : 78 - 79
  • [38] Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
    Ritzel, R.
    Roussel, R.
    Bolli, G. B.
    Vinet, L.
    Brulle-Wohlhueter, C.
    Glezer, S.
    Yki-Jaervinen, H.
    DIABETES OBESITY & METABOLISM, 2015, 17 (09): : 859 - 867
  • [39] Older people with type 2 diabetes: glycaemic control and hypoglycaemia risk with new insulin glargine 300 U/ml (Gla-300)
    Stella, P.
    Aroda, V.
    Charbonnel, B.
    Ritzel, R.
    Merino-Trigo, A.
    Grisoni, M. -L.
    Sinclair, A. J.
    Yale, J. -F.
    DIABETOLOGIA, 2015, 58 : S473 - S473
  • [40] Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
    Maffeis, Claudio
    Rabbone, Ivana
    PEDIATRIC DRUGS, 2022, 24 (05) : 499 - 512
12345